Explore 3 Stock Ideas & Industry Insights Download Free Report

Stocks

Digital Payment Update - Europe's Payment Future Embraces Digital Wallet Innovation

Significant growth in Europe's digital payments is anticipated by 2025, propelled by innovative payment methods and evolving consumer preferences. Digital wallets are at the forefront, seeing increasing weekly use in countries like the UK and Germany, while contactless payments continue to gain popularity. Despite …

EODHD | 12 May 2025

Here’s What Weighed On Target (TGT) Shares

Diamond Hill Capital, an investment management company, released its “Large Cap Fund” first-quarter 2025 investor letter. A copy of the letter can be downloaded here. Markets exhibited a mixed performance in Q1 as the new presidential administration generated significant buzz with a flurry of …

EODHD | 12 May 2025

SelectQuote (SLQT) Misses Q3 Earnings and Revenue Estimates

SelectQuote (SLQT) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.05 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …

EODHD | 12 May 2025

HAE Stock Gains on Q4 Earnings and Revenue Beat, Margins Up

Haemonetics Corporation HAE delivered fourth-quarter fiscal 2025 adjusted earnings per share (EPS) of $1.24, which rose 37.8% year over year. The bottom line topped the Zacks Consensus Estimate by 1.6%. On a GAAP basis, EPS was $1.17 compared with 40 cents in the prior-year …

EODHD | 12 May 2025

Iovance Biotherapeutics’ (IOVA) Annual Maintenance: Assurances Collide with Adverse Disclosure as Shares Plunge 44% – Hagens Berman

SAN FRANCISCO, May 12, 2025 (GLOBE NEWSWIRE) -- In a dramatic turn for Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), investors watched the company’s shares plunge nearly 44% on May 9, 2025, after the San Carlos-based cell therapy pioneer reported a first-quarter revenue miss that sharply …

EODHD | 12 May 2025

Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial

Adds nine additional countries to the Company’s ongoing pivotal Phase 3 trial; Authorization granted in all EU countries requested Enrollment and dosing underway in Phase 3 clinical trial (the “MIRACLE” trial) evaluating Annamycin for the treatment of R/R AML; Interim data readout expected in …

EODHD | 12 May 2025

Installed Building Products, Inc. Just Missed EPS By 12%: Here's What Analysts Think Will Happen Next

Last week, you might have seen that Installed Building Products, Inc. (NYSE:IBP) released its first-quarter result to the market. The early response was not positive, with shares down 5.5% to US$161 in the past week. It was not a great result overall. While revenues …

EODHD | 12 May 2025

Trump Tariffs: Shipping Stocks Jump On U.S.-China Trade Deal. Uncertainty Remains.

Trump tariffs on China have been temporarily slashed after successful U.S.-China trade talks. Shipping stocks were big winners. Continue Reading View Comments

EODHD | 12 May 2025

CHTR Q1 Earnings Call: Bundled Strategy and Efficiency Measures Take Center Stage

Cable, internet, and telephone services provider Charter (NASDAQ:CHTR) met Wall Street’s revenue expectations in Q1 CY2025, but sales were flat year on year at $13.74 billion. Its non-GAAP profit of $8.42 per share was 2% below analysts’ consensus estimates. Is now the time to …

EODHD | 12 May 2025

Rheinmetall First Quarter 2025 Earnings: Beats Expectations

Rheinmetall (ETR:RHM) First Quarter 2025 Results Key Financial Results Revenue: €2.31b (up 46% from 1Q 2024). Net income: €84.0m (up 71% from 1Q 2024). Profit margin: 3.6% (up from 3.1% in 1Q 2024). The increase in margin was driven by higher revenue. EPS: €1.92 …

EODHD | 12 May 2025
Support

Hi! How can we help you today?

Loading…